These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 17988867)

  • 21. Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer.
    Liauw W; Segelov E; Lih A; Dunleavy R; Links M; Ward R
    BMC Cancer; 2005 Jul; 5():89. PubMed ID: 16048654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials.
    Machado M; Cruz LS; Tannus G; Fonseca M
    Clin Ther; 2009 May; 31(5):962-79. PubMed ID: 19539097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancer.
    Hirsh V
    Clin Lung Cancer; 2009 Jul; 10(4):223-9. PubMed ID: 19632938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bisphosphonates in breast cancer: clinical activity and implications of preclinical data.
    Aft R
    Clin Adv Hematol Oncol; 2011 Mar; 9(3):194-205. PubMed ID: 21475125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
    Facchini G; Caraglia M; Santini D; Nasti G; Ottaiano A; Striano S; Maiolino P; Ruberto M; Fiore F; Tonini G; Budillon A; Iaffaioli RV; Zeppetella GL
    J Exp Clin Cancer Res; 2007 Sep; 26(3):307-12. PubMed ID: 17987788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bisphosphonates in lung cancer: more than a palliative therapy?
    Jahanzeb M; Hirsh V
    Semin Oncol; 2010 Jun; 37 Suppl 1():S45-52. PubMed ID: 20682372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The evolving role of bone-conserving therapy in patients with breast cancer.
    Brufsky AM
    Semin Oncol; 2010 Jun; 37 Suppl 1():S12-9. PubMed ID: 20682367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease.
    Saad F; Lipton A
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S17-23. PubMed ID: 18068486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Current use of bisphosphonates in clinical oncology].
    Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
    Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Bisphosphonates and breast cancer].
    Vehmanen L; Saarto T
    Duodecim; 2010; 126(10):1229-37. PubMed ID: 20597352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential anticancer properties of bisphosphonates.
    Neville-Webbe HL; Gnant M; Coleman RE
    Semin Oncol; 2010 Jun; 37 Suppl 1():S53-65. PubMed ID: 20682373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bisphosphonates for the prevention of bone metastases.
    Coleman RE
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):43-9. PubMed ID: 12584694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of bisphosphonates in cancer treatment.
    Coleman R
    Ann N Y Acad Sci; 2011 Feb; 1218():3-14. PubMed ID: 20946581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antitumour effects of bisphosphonates in breast cancer].
    van de Ven S; Kroep JR; Hamdy NA; Sleeboom HP; Nortier HW
    Ned Tijdschr Geneeskd; 2010; 154():A1951. PubMed ID: 21083955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Zoledronic acid in the treatment of metastatic breast cancer.
    Lluch A; Cueva J; Ruiz-Borrego M; Ponce J; Pérez-Fidalgo JA
    Anticancer Drugs; 2014 Jan; 25(1):1-7. PubMed ID: 24100278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of bisphosphonates in early breast cancer.
    Paterson AH
    Oncologist; 2006; 11 Suppl 1():13-9. PubMed ID: 16971735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence.
    Smith MR
    Cancer Treat Rev; 2005; 31 Suppl 3():19-25. PubMed ID: 16229955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Breast cancer: bisphosphonate therapy for metastatic bone disease.
    Body JJ
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6258s-6263s. PubMed ID: 17062710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Approaches to managing bone metastases from breast cancer: the role of bisphosphonates.
    Mystakidou K; Katsouda E; Stathopoulou E; Vlahos L
    Cancer Treat Rev; 2005 Jun; 31(4):303-11. PubMed ID: 16039956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.